Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 13, 2020

GeneCentric, Janssen collaborate to study genomic drug response biomarkers for NMIBC

GeneCentric Therapeutics has announced a research collaboration with Janssen Research & Development on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).

GeneCentric and Janssen have collaborated to study genomic drug response biomarkers for non-muscle invasive bladder cancer. (Credit: Emilian Danaila from Pixabay)